Evidence map›Paper›PMID 37247177›Full record

SynthesisIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2023

Fecal microbiota transplant delivered via invasive routes in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.

Babu P Mohan, Priyadarshini Loganathan, Shahab R Khan, Gauri Garg, Arunkumar Muthusamy, Suresh Ponnada, Ravi Teja Pasam, Saurabh Chandan, Ashok Tuteja

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Babu P Mohan *Gastroenterology and Hepatology, Veterans Affairs Medical Center and University of Utah Health School of Medicine, 30 N 1900 E SOM 4R118, Salt Lake City, UT, 84132, USA. dr.babu.pm@gmail.com.
Priyadarshini Loganathan *Internal Medicine, UT Health, San Antonio, TX, USA.
Shahab R KhanBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Gauri GargGastroenterology and Hepatology, Veterans Affairs Medical Center and University of Utah Health School of Medicine, 30 N 1900 E SOM 4R118, Salt Lake City, UT, 84132, USA.
Arunkumar MuthusamyGastroenterology and Hepatology, MNGI Digestive Health, Minnesota, MA, USA.
Suresh PonnadaInternal Medicine, Carilion Roanoke Medical Center, Roanoke, VA, USA.
Ravi Teja PasamInternal Medicine, Wentworth Hospital, Dover, NH, USA.
Saurabh ChandanGastroenterology and Hepatology, CHI Creighton School of Medicine, Omaha, NE, USA.
Ashok TutejaGastroenterology and Hepatology, Veterans Affairs Medical Center and University of Utah Health School of Medicine, 30 N 1900 E SOM 4R118, Salt Lake City, UT, 84132, USA.
University of Utah · USBrigham and Women's Hospital · USCarilion Clinic · USCreighton University · USMinnesota Gastroenterology · USThe University of Texas Health Science Center at Houston · USWentworth Douglass Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsIrritable bowel syndrome (IBS) results in significant loss of quality of life. Management guidelines do not recommend fecal microbiota transplant (FMT) for IBS based on weak evidence as refined data is lacking. We performed a systematic review and meta-analysis to ascertain the pooled clinical outcomes of FMT in IBS, delivered via invasive routes.

methodsMultiple databases were searched through January 2023 to identify studies that reported on FMT treatment in IBS by invasive routes. Standard meta-analysis methodology using the random-effects model was used. Heterogeneity was assessed by I

resultsFive studies were included. As many as 377 IBS patients were assessed, of which 238 received FMT and 139 received placebo. One study used nasojejunal tubes, one esophagogastroduodenoscopy and three colonoscopy for FMT delivery. FMT via colonoscopy was performed as a one-time procedure instilled into the cecum. Two studies used 30 g of stool from a single universal donor and one study used 50-80 g of pooled donor feces. The pooled odds ratio of improvement in IBS symptoms with FMT was significantly better as compared to that of placebo OR = 2.9 (95% CI [1.6-5.2, I

conclusionFMT delivered via invasive routes, especially colonoscopy, demonstrated significant improvement in IBS symptoms. A single FMT consisting of 30 g or more of single universal donor feces instilled into the cecum is the predominant modality.

Indexed as

Gastrointestinal MicrobiomeIrritable Bowel SyndromeFecal Microbiota TransplantationFecesHumansQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeBloatingColonoscopyConstipationDiarrheaFMTIBSMeta-analysisROME criteria

Identifiers

PMID37247177
PMCPMC10225764
OpenAlexW4378611308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.